Form 4: Kairos Pharma CEO John Yu Boosts Stake with RSU Grant

Kairos Pharma's CEO and Chairman, John S. Yu, reported the acquisition of 190,840 restricted stock units, increasing his beneficial ownership.

Summary

• John S. Yu, CEO and Chairman of Kairos Pharma, LTD. (KAPA), acquired 190,840 restricted stock units (RSUs).
• The RSUs were issued under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan at an acquisition price of $0.00.
• These 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date, October 8, 2026.
• Following this transaction, Mr. Yu directly beneficially owns 230,105 securities, which consist of 34,599 shares of common stock and 195,506 RSUs that remain subject to vesting.
• He also indirectly beneficially owns 5,316,572 shares of common stock through The Yu Family Trust.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to the CEO is generally positive as it aligns management's interests with long-term shareholder value, indicating confidence and commitment from leadership. It's an incentive for future performance rather than a direct cash investment.

Positives

• CEO John S. Yu received a grant of 190,840 restricted stock units, which aligns his interests with long-term shareholder value.
• The grant is part of the company's 2023 Equity Incentive Plan, indicating ongoing incentive programs for key personnel.

Future Outlook

The grant of restricted stock units with a one-year vesting period indicates a future incentive for the CEO, aligning his long-term interests with the company's performance and strategic goals.

Industry Context

Insider equity grants are a common practice across industries, particularly in biotechnology and pharmaceuticals, to incentivize and retain key executives. This practice links executive compensation to the company's stock performance and long-term value creation, fostering alignment between leadership and shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a CEO is a standard compensation practice, comparable to similar equity incentive plans at biotechnology and pharmaceutical companies like Moderna (MRNA) or BioNTech (BNTX), which frequently use RSUs to align executive interests with shareholder value.
• A $0.00 acquisition price for RSUs is typical, as these represent future equity awards rather than a direct cash purchase, similar to how many tech and biotech companies structure executive compensation.
• The one-year vesting schedule for the RSUs is a common, though sometimes shorter, period compared to multi-year vesting schedules seen in some larger corporations, which might span 3-5 years to encourage longer-term retention.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with the company's long-term performance and stock value.
• Employees: May signal stability and continued executive commitment to the company's future.

Next Steps

• The 190,840 restricted stock units are scheduled to vest in full on October 8, 2026.

Key Dates

Recommendation

The Form 4 filing indicates an equity grant to the CEO, which is a positive for aligning management incentives with shareholder interests. However, it does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance, acknowledging management's continued commitment without suggesting a change in the company's fundamental outlook based solely on this disclosure.

Keywords

Kairos Pharma, KAPA, John S. Yu, Restricted Stock Units, RSU, Insider Trading, SEC Form 4, Equity Incentive Plan, CEO, Chairman, Beneficial Ownership